Cargando…
A case of PD-L1 negative advanced pulmonary sarcomatoid carcinoma effectively treated with atezolizumab, carboplatin, paclitaxel, and bevacizumab
Pulmonary sarcomatoid carcinoma (PSC) is an extremely rare neoplasm with poor prognosis and no established treatment. A 50-year-old man presented with fever, was found to have a mass measuring 14 cm in the right upper lobe of the chest, along with right pleural effusion on computed tomography (CT)....
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8760426/ https://www.ncbi.nlm.nih.gov/pubmed/35059287 http://dx.doi.org/10.1016/j.rmcr.2022.101579 |
_version_ | 1784633317397626880 |
---|---|
author | Sawatari, Kosuke Izumi, Motohiro Sone, Risa Hattori, Tsuyoshi Sugimoto, Akira Eguchi, Yosuke Mamoto, Takashi |
author_facet | Sawatari, Kosuke Izumi, Motohiro Sone, Risa Hattori, Tsuyoshi Sugimoto, Akira Eguchi, Yosuke Mamoto, Takashi |
author_sort | Sawatari, Kosuke |
collection | PubMed |
description | Pulmonary sarcomatoid carcinoma (PSC) is an extremely rare neoplasm with poor prognosis and no established treatment. A 50-year-old man presented with fever, was found to have a mass measuring 14 cm in the right upper lobe of the chest, along with right pleural effusion on computed tomography (CT). Positron emission tomography-CT revealed abnormal tracer uptake in the area corresponding to the mass in the upper lobe. Hence, convex-probe endobronchial ultrasound-guided transbronchial needle aspiration was performed. Histological examination revealed dense proliferation of spindle tumor cells and no programmed death-ligand 1 (PD-L1) expression. Thus, he was diagnosed with PSC (cT4N0M1a, clinical stage IVA), and four-agent combination chemotherapy with atezolizumab, carboplatin, paclitaxel, and bevacizumab was initiated. Marked shrinkage of the mass and symptomatic improvements were observed following the treatment initiation. Tumor shrinkage was further noted after shifting to maintenance therapy with atezolizumab and bevacizumab; the patient exhibited no symptom exacerbation 2 years later and continued the treatment. Our case showed that four-agent combination chemotherapy with atezolizumab, carboplatin, paclitaxel, and bevacizumab could be an effective treatment option for advanced PSC with or without PD-L1 expression. |
format | Online Article Text |
id | pubmed-8760426 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-87604262022-01-19 A case of PD-L1 negative advanced pulmonary sarcomatoid carcinoma effectively treated with atezolizumab, carboplatin, paclitaxel, and bevacizumab Sawatari, Kosuke Izumi, Motohiro Sone, Risa Hattori, Tsuyoshi Sugimoto, Akira Eguchi, Yosuke Mamoto, Takashi Respir Med Case Rep Case Report Pulmonary sarcomatoid carcinoma (PSC) is an extremely rare neoplasm with poor prognosis and no established treatment. A 50-year-old man presented with fever, was found to have a mass measuring 14 cm in the right upper lobe of the chest, along with right pleural effusion on computed tomography (CT). Positron emission tomography-CT revealed abnormal tracer uptake in the area corresponding to the mass in the upper lobe. Hence, convex-probe endobronchial ultrasound-guided transbronchial needle aspiration was performed. Histological examination revealed dense proliferation of spindle tumor cells and no programmed death-ligand 1 (PD-L1) expression. Thus, he was diagnosed with PSC (cT4N0M1a, clinical stage IVA), and four-agent combination chemotherapy with atezolizumab, carboplatin, paclitaxel, and bevacizumab was initiated. Marked shrinkage of the mass and symptomatic improvements were observed following the treatment initiation. Tumor shrinkage was further noted after shifting to maintenance therapy with atezolizumab and bevacizumab; the patient exhibited no symptom exacerbation 2 years later and continued the treatment. Our case showed that four-agent combination chemotherapy with atezolizumab, carboplatin, paclitaxel, and bevacizumab could be an effective treatment option for advanced PSC with or without PD-L1 expression. Elsevier 2022-01-04 /pmc/articles/PMC8760426/ /pubmed/35059287 http://dx.doi.org/10.1016/j.rmcr.2022.101579 Text en © 2022 The Authors. Published by Elsevier Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Case Report Sawatari, Kosuke Izumi, Motohiro Sone, Risa Hattori, Tsuyoshi Sugimoto, Akira Eguchi, Yosuke Mamoto, Takashi A case of PD-L1 negative advanced pulmonary sarcomatoid carcinoma effectively treated with atezolizumab, carboplatin, paclitaxel, and bevacizumab |
title | A case of PD-L1 negative advanced pulmonary sarcomatoid carcinoma effectively treated with atezolizumab, carboplatin, paclitaxel, and bevacizumab |
title_full | A case of PD-L1 negative advanced pulmonary sarcomatoid carcinoma effectively treated with atezolizumab, carboplatin, paclitaxel, and bevacizumab |
title_fullStr | A case of PD-L1 negative advanced pulmonary sarcomatoid carcinoma effectively treated with atezolizumab, carboplatin, paclitaxel, and bevacizumab |
title_full_unstemmed | A case of PD-L1 negative advanced pulmonary sarcomatoid carcinoma effectively treated with atezolizumab, carboplatin, paclitaxel, and bevacizumab |
title_short | A case of PD-L1 negative advanced pulmonary sarcomatoid carcinoma effectively treated with atezolizumab, carboplatin, paclitaxel, and bevacizumab |
title_sort | case of pd-l1 negative advanced pulmonary sarcomatoid carcinoma effectively treated with atezolizumab, carboplatin, paclitaxel, and bevacizumab |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8760426/ https://www.ncbi.nlm.nih.gov/pubmed/35059287 http://dx.doi.org/10.1016/j.rmcr.2022.101579 |
work_keys_str_mv | AT sawatarikosuke acaseofpdl1negativeadvancedpulmonarysarcomatoidcarcinomaeffectivelytreatedwithatezolizumabcarboplatinpaclitaxelandbevacizumab AT izumimotohiro acaseofpdl1negativeadvancedpulmonarysarcomatoidcarcinomaeffectivelytreatedwithatezolizumabcarboplatinpaclitaxelandbevacizumab AT sonerisa acaseofpdl1negativeadvancedpulmonarysarcomatoidcarcinomaeffectivelytreatedwithatezolizumabcarboplatinpaclitaxelandbevacizumab AT hattoritsuyoshi acaseofpdl1negativeadvancedpulmonarysarcomatoidcarcinomaeffectivelytreatedwithatezolizumabcarboplatinpaclitaxelandbevacizumab AT sugimotoakira acaseofpdl1negativeadvancedpulmonarysarcomatoidcarcinomaeffectivelytreatedwithatezolizumabcarboplatinpaclitaxelandbevacizumab AT eguchiyosuke acaseofpdl1negativeadvancedpulmonarysarcomatoidcarcinomaeffectivelytreatedwithatezolizumabcarboplatinpaclitaxelandbevacizumab AT mamototakashi acaseofpdl1negativeadvancedpulmonarysarcomatoidcarcinomaeffectivelytreatedwithatezolizumabcarboplatinpaclitaxelandbevacizumab AT sawatarikosuke caseofpdl1negativeadvancedpulmonarysarcomatoidcarcinomaeffectivelytreatedwithatezolizumabcarboplatinpaclitaxelandbevacizumab AT izumimotohiro caseofpdl1negativeadvancedpulmonarysarcomatoidcarcinomaeffectivelytreatedwithatezolizumabcarboplatinpaclitaxelandbevacizumab AT sonerisa caseofpdl1negativeadvancedpulmonarysarcomatoidcarcinomaeffectivelytreatedwithatezolizumabcarboplatinpaclitaxelandbevacizumab AT hattoritsuyoshi caseofpdl1negativeadvancedpulmonarysarcomatoidcarcinomaeffectivelytreatedwithatezolizumabcarboplatinpaclitaxelandbevacizumab AT sugimotoakira caseofpdl1negativeadvancedpulmonarysarcomatoidcarcinomaeffectivelytreatedwithatezolizumabcarboplatinpaclitaxelandbevacizumab AT eguchiyosuke caseofpdl1negativeadvancedpulmonarysarcomatoidcarcinomaeffectivelytreatedwithatezolizumabcarboplatinpaclitaxelandbevacizumab AT mamototakashi caseofpdl1negativeadvancedpulmonarysarcomatoidcarcinomaeffectivelytreatedwithatezolizumabcarboplatinpaclitaxelandbevacizumab |